Ipca Laboratories is currently trading at Rs. 669.35, up by 7.40 points or 1.12% from its previous closing of Rs. 661.95 on the BSE.
The scrip opened at Rs. 665.00 and has touched a high and low of Rs. 671.30 and Rs. 665.00 respectively. So far 98 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 822.80 on 09-Aug-2018 and a 52 week low of Rs. 444.00 on 24-Oct-2017.
Last one week high and low of the scrip stood at Rs. 705.70 and Rs. 647.10 respectively. The current market cap of the company is Rs. 8363.88 crore.
The promoters holding in the company stood at 46.07%, while Institutions and Non-Institutions held 39.84% and 14.09% respectively.
Ipca Laboratories’ wholly owned subsidiary -- Ipca Pharmaceuticals Inc., USA has acquired 80% share capital of Bayshore Pharmaceuticals LLC (Bayshore), a New Jersey liability company on October 2, 2018, for cash of $10.286 million. The acquired company belongs to Sales and Marketing of FDA approved Generics Drug Products in the United States of America.
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1850.40 |
| Dr. Reddys Lab | 1310.50 |
| Cipla | 1365.25 |
| Zydus Lifesciences | 939.10 |
| Lupin | 2442.35 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: